Columbia genome engineers are designing a CRISPR-based gene therapy with potential to prevent blindness in anyone with retinitis pigmentosa, a condition caused by more than 80 different genes.
Most people are familiar with melanoma as a skin cancer, but melanoma can impact the eyes as well. Brian Marr, MD, offers tips on how to protect your eyes.
A new study in mice, led by Columbia University researchers, suggests experimental eye drops may be more effective than injections for treatment of retinal vein occlusion, a major cause of blindness.
New genetic findings should help researchers uncover how MacTel, a disease of the retina, develops and how to design therapies to prevent loss of vision.
Columbia University researchers slowed vision loss in mice who have a form of retinitis pigmentosa by reprogramming the metabolism of photoreceptors in the retina.
Columbia University Medical Center researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa, a leading cause of vision loss.
Dr. Janet Sparrow and colleagues are pioneering a new way to use the retina's natural fluorescence to track and characterize the progression of eye diseases.
Using stem cells from patients, P&S researchers have created a model of age-related macular degeneration in a dish, which may lead personalized treatments to prevent vision loss.